Clinical and laboratory features of seven patients with acute myeloid leukemia (AML)-M2/M3 and elevated myeloblasts and abnormal promyelocytes

Table 5 Follow-up of 7 patients with AML-M2/M3 until 30th june, 2012

	Chemotherapy treatment	Subsequent	Time*(days, d)	Final diagnosis
	In our deparmett	Treatment	Time*(days, d)	Final diagnosis
Case 1	3 cycles	allo-SCT**	1630d	CR
Case 2	4 cycles	auto-SCT	1492d	CR
Case 3	1 cycle	-	3d	Death
Case 4	5 cycles	allo-SCT	766d	CR
Case 5	1 cycle	-	>29d	Non-remission, lost at follow-up
Case 6	4 cycles	-	467d	Recurrence, transformed into AMLM2
Case 7	1 cycle	-	53d	CR

allo-SCT, allogeneic stem cell transplantation; auto-SCT: autologous stem cell transplantation.
*closing date: 30 June, 2012.
^**the patient had the allo-SCT in another hospital.

ISSN: 1475-2867